74 related articles for article (PubMed ID: 31735627)
1. The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability.
Huang Y; Mouttet B; Warnatz HJ; Risch T; Rietmann F; Frommelt F; Ngo QA; Dobay MP; Marovca B; Jenni S; Tsai YC; Matzk S; Amstislavskiy V; Schrappe M; Stanulla M; Gstaiger M; Bornhauser B; Yaspo ML; Bourquin JP
Cancer Cell; 2019 Dec; 36(6):630-644.e9. PubMed ID: 31735627
[TBL] [Abstract][Full Text] [Related]
2. A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer.
Chen H; Liang H
Cancer Cell; 2020 Nov; 38(5):701-715.e5. PubMed ID: 33007258
[TBL] [Abstract][Full Text] [Related]
3. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
4. Targeting the oncogenic activity of TCF3-HLF in leukemia.
Huang Y; Bourquin JP
Mol Cell Oncol; 2020; 7(3):1709391. PubMed ID: 32391417
[TBL] [Abstract][Full Text] [Related]
5. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Laurent AP; Siret A; Ignacimouttou C; Panchal K; Diop M; Jenni S; Tsai YC; Roos-Weil D; Aid Z; Prade N; Lagarde S; Plassard D; Pierron G; Daudigeos E; Lecluse Y; Droin N; Bornhauser BC; Cheung LC; Crispino JD; Gaudry M; Bernard OA; Macintyre E; Barin Bonnigal C; Kotecha RS; Geoerger B; Ballerini P; Bourquin JP; Delabesse E; Mercher T; Malinge S
Clin Cancer Res; 2020 Jul; 26(13):3307-3318. PubMed ID: 32220889
[TBL] [Abstract][Full Text] [Related]
6. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.
Krupar R; Watermann C; Idel C; Ribbat-Idel J; Offermann A; Pasternack H; Kirfel J; Sikora AG; Perner S
Sci Rep; 2020 Jun; 10(1):9389. PubMed ID: 32523042
[TBL] [Abstract][Full Text] [Related]
7. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
8. Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling.
Gao J; Wei B; Liu M; Hirsova P; Sehrawat TS; Cao S; Hu X; Xue F; Yaqoob U; Kang N; Cui H; Pomerantz WCK; Kostallari E; Shah VH
Hepatology; 2021 Jun; 73(6):2468-2483. PubMed ID: 33159815
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Reader BRD4 (Bromodomain-Containing Protein 4) Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function.
Kim SY; Zhang X; Schiattarella GG; Altamirano F; Ramos TAR; French KM; Jiang N; Szweda PA; Evers BM; May HI; Luo X; Li H; Szweda LI; Maracaja-Coutinho V; Lavandero S; Gillette TG; Hill JA
Circulation; 2020 Dec; 142(24):2356-2370. PubMed ID: 33113340
[TBL] [Abstract][Full Text] [Related]
10. BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage.
Lam FC; Kong YW; Huang Q; Vu Han TL; Maffa AD; Kasper EM; Yaffe MB
Nat Commun; 2020 Aug; 11(1):4083. PubMed ID: 32796829
[TBL] [Abstract][Full Text] [Related]
11. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
12. Modeling and targeting of erythroleukemia by hematopoietic genome editing.
Iacobucci I; Qu C; Varotto E; Janke LJ; Yang X; Seth A; Shelat A; Friske JD; Fukano R; Yu J; Freeman BB; Kennedy JA; Sperling AS; Zheng R; Wang Y; Jogiraju H; Dickerson KM; Payne-Turner D; Morris SM; Hollis ES; Ghosn N; Haggard GE; Lindsley RC; Ebert BL; Mullighan CG
Blood; 2021 Mar; 137(12):1628-1640. PubMed ID: 33512458
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological disruption of the Notch transcription factor complex.
Lehal R; Zaric J; Vigolo M; Urech C; Frismantas V; Zangger N; Cao L; Berger A; Chicote I; Loubéry S; Choi SH; Koch U; Blacklow SC; Palmer HG; Bornhauser B; González-Gaitán M; Arsenijevic Y; Zoete V; Aster JC; Bourquin JP; Radtke F
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16292-16301. PubMed ID: 32601208
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
15. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.
Bornhauser B; Cario G; Rinaldi A; Risch T; Rodriguez Martinez V; Schütte M; Warnatz HJ; Scheidegger N; Mirkowska P; Temperli M; Möller C; Schumich A; Dworzak M; Attarbaschi A; Brüggemann M; Ritgen M; Mejstrikova E; Hofmann A; Buldini B; Scarparo P; Basso G; Maglia O; Gaipa G; Skoblyn TL; Te Kronnie G; Vendramini E; Panzer-Grümayer R; Barz MJ; Marovca B; Hauri-Hohl M; Niggli F; Eckert C; Schrappe M; Stanulla M; Zimmermann M; Wollscheid B; Yaspo ML; Bourquin JP
Blood Adv; 2020 Sep; 4(17):4052-4064. PubMed ID: 32853382
[TBL] [Abstract][Full Text] [Related]
16. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Fagnan A; Bagger FO; Piqué-Borràs MR; Ignacimouttou C; Caulier A; Lopez CK; Robert E; Uzan B; Gelsi-Boyer V; Aid Z; Thirant C; Moll U; Tauchmann S; Kurtovic-Kozaric A; Maciejewski J; Dierks C; Spinelli O; Salmoiraghi S; Pabst T; Shimoda K; Deleuze V; Lapillonne H; Sweeney C; De Mas V; Leite B; Kadri Z; Malinge S; de Botton S; Micol JB; Kile B; Carmichael CL; Iacobucci I; Mullighan CG; Carroll M; Valent P; Bernard OA; Delabesse E; Vyas P; Birnbaum D; Anguita E; Garçon L; Soler E; Schwaller J; Mercher T
Blood; 2020 Aug; 136(6):698-714. PubMed ID: 32350520
[TBL] [Abstract][Full Text] [Related]
17. Aurora A kinase as a target for therapy in
Leonard J; Wolf JS; Degnin M; Eide CA; LaTocha D; Lenz K; Wilmot B; Mullighan CG; Loh M; Hunger SP; Druker BJ; Loriaux MM; Tyner JW; Chang BH
Haematologica; 2021 Nov; 106(11):2990-2994. PubMed ID: 34233449
[No Abstract] [Full Text] [Related]
18. Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.
Lejman M; Włodarczyk M; Zawitkowska J; Kowalczyk JR
BMC Med Genomics; 2020 Apr; 13(1):58. PubMed ID: 32245383
[TBL] [Abstract][Full Text] [Related]
19.
Tasian SK
Haematologica; 2023 Jul; 108(7):1713-1714. PubMed ID: 37392046
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
